COVINA, Calif., May 12 /PRNewswire/ -- StemCyte Inc. today announced that it has relocated its California operations from Arcadia to a 36,000-square- foot facility in Covina.

The new facility will provide StemCyte with increased storage capacity for its supply of plasma-depleted umbilical cord blood (UCB) stem cell products. In addition, the Covina facility will house StemCyte executives and researchers.

Our UCB stem cell products are already being used to treat patients with over 35 different diseases in 32 different countries," said Kenneth J. Giacin, chairman and chief executive officer of StemCyte. "The new Covina facility is an integral part of our plan to build the largest, most diverse supply of UCB stem cell products to ensure we are able to treat even more patients."

In addition to Covina, StemCyte's operations are located in New Jersey and Taiwan. The company is also developing StemCyte India Therapeutics in Ahmedabad in collaboration with Apollo Hospitals and Cadila Pharmaceuticals.

About StemCyte Inc.

StemCyte Inc. is a global cell therapy company with a focus on umbilical cord blood (UCB) stem cells. Since 2001, the company's stem cell products have been used to successfully treat more than 600 patients suffering from life-threatening diseases and conditions. StemCyte also has a leadership position in the development of new cell therapies in high-growth areas with the greatest clinical need. The company is accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). For more information, visit www.stemcyte.com.